Borroni B et al. Clinical and neuroradiological features of spinocerebellar ataxia 38 (SCA38). Parkinsonism Relat Disord. 2016;28:80–6. PMID: 27143115.
Di Gregorio E et al. ELOVL5 mutations cause spinocerebellar ataxia 38. Am J Hum Genet. 2014;95:209–17. PMID: 25065913.
Gazulla J et al. Contributions to the study of spinocerebellar ataxia type 38 (SCA38). J Neurol 2020 Aug;267(8):2288-2295. PMID: 32314013.
Hoxha E et al. Motor deficits and cerebellar atrophy in Elovl5 knock out mice. Front Cell Neurosci. 2017;11:343. PMID: 29163054.
Liu Z et al. SCA38 is rare in Mainland China. J Neurol Sci. 2015;358:333–4. PMID: 26433464.
Manes M et al. Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38. Ann Neurol. 2017;82:615–21. PMID: 28976605.
Manes M et al. Long-term efficacy of docosahexaenoic acid (DHA) for spinocerebellar ataxia 38 (SCA38) treatment: an open label extension study. Parkinsonism Relat Disord 2019 Jun;63:191-194. PMID: 30862453.